Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure

Takaya,Hiroaki; Yoshiji,Hitoshi; Kawaratani,Hideto; Sakai,Kazuya; Matsumoto,Masanori; Fujimura,Yoshihiro; Fukui,Hiroshi

doi:10.3892/br.2017.945

Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure

Authors:
- Hiroaki Takaya
- Hitoshi Yoshiji
- Hideto Kawaratani
- Kazuya Sakai
- Masanori Matsumoto
- Yoshihiro Fujimura
- Hiroshi Fukui
View Affiliations

Affiliations: Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634‑8522, Japan, Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara 634‑8522, Japan
Published online on: July 19, 2017 https://doi.org/10.3892/br.2017.945
Pages: 277-285

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deficient ADAM metalloproteinase with thrombospondin type‑1 motif, member 13 (ADAMTS13) activity (ADAMTS13:AC) results in the accumulation of unusually large von Willebrand factor multimers (UL‑VWFM) and causes microcirculatory disturbances and multiple organ failure, while endotoxins trigger the activation of a coagulation cascade. The objective of the present study was to explore the role of ADAMTS13 in endotoxemia in patients with acute liver failure (ALF). Plasma concentrations of endotoxin and cytokines, including interleukin (IL)‑6 and IL‑8, and activity of the plasma ADAMTS13 inhibitor were determined, along with ADAMTS13:AC, the VWF antigen (VWF:Ag) and UL‑VWFM, in 27 patients with acute hepatitis (AH), 11 patients with ALF, and 10 healthy controls. IL‑6 and IL‑8 concentrations on admission were significantly higher in patients with ALF than in those with AH or in healthy controls. ADAMTS13:AC concomitantly decreased and VWF:Ag progressively increased with increasing cytokine concentrations from the normal range to >100 pg/ml. The inhibitor was detected in 8 patients with ALF (0.6 to 2.4 BU/ml) and 6 patients with AH (0.6 to 0.8 BU/ml). Patients with the inhibitor reported lower ADAMTS13:AC, higher VWF:Ag and lower functional liver capacity than those without the inhibitor. Collectively, the findings suggested that decreased ADAMTS13:AC and increased VWF:Ag may be induced by pro‑inflammatory cytokinemia as well as the presence of the ADAMTS13 inhibitor, both of which may be closely related to enhanced endotoxemia in patients with ALF.

View Figures

View References

1	Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE and Fujikawa K: Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 276:41059–41063. 2001. View Article : Google Scholar : PubMed/NCBI
2	Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H and Fujimura Y: Localization of ADAMTS13 to the stellate cells of human liver. Blood. 106:922–924. 2005. View Article : Google Scholar : PubMed/NCBI
3	Moake JL, Turner NA, Stathopoulos NA, Nolasco LH and Hellums JD: Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 78:1456–1461. 1986. View Article : Google Scholar : PubMed/NCBI
4	Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, et al: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 413:488–494. 2001. View Article : Google Scholar : PubMed/NCBI
5	Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, et al: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 339:1578–1584. 1998. View Article : Google Scholar : PubMed/NCBI
6	Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR, Ballard RB, Terrell DR, Vesely SK, George JN and Marques MB: First symptoms in patients with thrombotic thrombocytopenic purpura: What are they and when do they occur? Transfusion. 53:235–237. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ishikawa M, Uemura M, Matsuyama T, Matsumoto M, Ishizashi H, Kato S, Morioka C, Fujimoto M, Kojima H, Yoshiji H, et al: Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. Alcohol Clin Exp Res. 34 Suppl 1:25–33. 2010. View Article : Google Scholar
8	Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, et al: Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 99:1019–1029. 2008.PubMed/NCBI
9	Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT and Lisman T: An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. Hepatology. 58:752–761. 2013. View Article : Google Scholar : PubMed/NCBI
10	Fukui H: Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. Alcohol Clin Exp Res. 29:172S–179S. 2005. View Article : Google Scholar : PubMed/NCBI
11	Nolan JP: The role of intestinal endotoxin in liver injury: A long and evolving history. Hepatology. 52:1829–1835. 2010. View Article : Google Scholar : PubMed/NCBI
12	Cao WJ, Niiya M, Zheng XW, Shang DZ and Zheng XL: Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 6:1233–1235. 2008. View Article : Google Scholar : PubMed/NCBI
13	Bernardo A, Ball C, Nolasco L, Moake JF and Dong JF: Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 104:100–106. 2004. View Article : Google Scholar : PubMed/NCBI
14	Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, Reinhart K and Brunkhorst FM: Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 93:137–140. 2008. View Article : Google Scholar : PubMed/NCBI
15	Mochida S, Nakayama N, Ido A, Takikawa Y, Yokosuka O, Sakaida I, Moriwaki H, Genda T and Takikawa H: Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: A report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res. 46:369–371. 2016. View Article : Google Scholar : PubMed/NCBI
16	Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A, Yagi H, Park YD, Takeshima Y, Kosaka Y, et al: Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant. 40:251–259. 2007. View Article : Google Scholar : PubMed/NCBI
17	Koyama N, Matsumoto M, Tamaki S, Yoshikawa M, Fujimura Y and Kimura H: Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnoeic episodes. Eur Respir J. 40:657–664. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, et al: Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 34:6121975.PubMed/NCBI
19	Fukui H, Brauner B, Bode JC and Bode C: Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: Reevaluation with an improved chromogenic assay. J Hepatol. 12:162–169. 1991. View Article : Google Scholar : PubMed/NCBI
20	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
21	Shah N, de Oca M Montes, Jover-Cobos M, Tanamoto K, Muroi M, Sugiyama K, Davies NA, Mookerjee RP, Dhar DK and Jalan R: Role of toll-like receptor 4 in mediating multiorgan dysfunction in mice with acetaminophen induced acute liver failure. Liver Transpl. 19:751–761. 2013. View Article : Google Scholar : PubMed/NCBI
22	Melgaço JG, Soriani FM, Sucupira PH, Pinheiro LA, Vieira YR, de Oliveira JM, Lewis-Ximenez LL, Araújo CC, Pacheco-Moreira LF, Menezes GB, et al: Changes in cellular proliferation and plasma products are associated with liver failure. World J Hepatol. 8:1370–1383. 2016. View Article : Google Scholar : PubMed/NCBI
23	Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R and Jalan R: Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl. 13:400–405. 2007. View Article : Google Scholar : PubMed/NCBI
24	Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J and Williams R: The systemic inflammatory response syndrome in acute liver failure. Hepatology. 32:734–739. 2000. View Article : Google Scholar : PubMed/NCBI
25	Shinozaki K, Oda S, Abe R, Tateishi Y, Yokoi T and Hirasawa H: Blood purification in fulminant hepatic failure. Contrib Nephrol. 166:64–72. 2010. View Article : Google Scholar : PubMed/NCBI
26	Fujimoto M, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, Kitano H, Kikukawa M, Ann T, Ishii Y, et al: Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: Relation to severity of liver disturbance. Alcohol Clin Exp Res. 24 Suppl:48S–54S. 2000.PubMed/NCBI
27	Fukui H, Brauner B, Bode JC and Bode C: Chromogenic endotoxin assay in plasma. Selection of plasma pretreatment and production of standard curves. J Clin Chem Clin Biochem. 27:941–946. 1989.PubMed/NCBI
28	Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T and Sakata Y: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood. 107:528–534. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M and Fujimura Y: Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol. 42:420–421. 2005. View Article : Google Scholar : PubMed/NCBI
30	Kitano K, Gibo Y, Kamijo A, Furuta K, Oguchi S, Joshita S, Takahashi Y, Ishida F, Matsumoto M, Uemura M and Fujimura Y: Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica. 91:ECR342006.PubMed/NCBI
31	Reiter RA, Varadi K, Turecek PL, Jilma B and Knöbl P: Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 93:554–558. 2005.PubMed/NCBI